A major milestone for Elucid: FFR-IQ™ is now FDA-cleared and commercially available! Read the full announcement: elucid.com/elucid-announces-… We're proud to introduce BioIntegrated FFR-CT, a new approach to noninvasive coronary physiology assessment that integrates coronary anatomy and plaque composition to support more accurate, personalized treatment decisions. In the ELUCIDATE FFR-CT study, FFR-IQ demonstrated: · 92.2% sensitivity · 93.1% specificity · The highest reported diagnostic performance among FDA-cleared FFR-CT validation studies.¹ Together, FFR-IQ™ and Plaque-IQ™ bring coronary anatomy, plaque biology, and physiology into one comprehensive platform, enabling physicians to better understand both individual lesions and the patient's broader coronary disease from a single CCTA. 📍 Join us at #TCT2026, where results from the ELUCIDATE FFR-CT study will be presented on November 1. Visit us at booth #3424 to learn more. ¹ Elucid FFR-IQ (B.1). FDA 510(k) Summary, K262015. September 29, 2026. Highest reported performance among FDA-cleared FFR-CT validation studies. #Elucid #FFRIQ #FFRCT #cardiovascularimaging #CCTA #cardiology #precisionmedicine #TCT2026

What if you could see beyond stenosis to better understand which lesions are truly limiting coronary blood flow? Join Elucid at #TCT2026 for one of our two hands-on sessions in the Physiology Training Pavilion on November 1! Experience how FFR-IQ™ and Plaque-IQ™ bring coronary anatomy, plaque biology, and physiology together from a single CCTA, providing a more comprehensive picture of coronary disease to help inform invasive evaluation, revascularization decisions, and personalized patient care. Discover how better insights before the cath lab can support more precise decisions in the cath lab. Have follow up questions from the session? Visit us at booth 3424 for 1:1 time. 📍 TCT Physiology Training Pavilion | November 1 2PM PT and 4PM PT tctconference.com/program-gu… #TCT2026 #interventionalcardiology #FFRCT #CCTA #PrecisionMedicine

Register here: scct.org/events/EventDetails… 🫀 Join Drs. @GreggWStone, @amir_ahmadi__, and @PraveenRangana9 for our upcoming sponsored webinar THIS WEDNESDAY at 1PM ET, hosted by Society of Cardiovascular Computed Tomography! Hear how emerging approaches to coronary imaging are connecting plaque biology, physiology, and lesion-level risk with more personalized treatment strategies, including the evolving roles of systemic medical therapy and focal intervention. Can't join us live? Register at the link above to get the recording sent to your inbox. See you there! #cardiology #precisionmedicine #yesCCT

We're headed to #TCT2026 in San Diego! Visit us at Booth 3424 to see how Plaque-IQ™ and BioIntegrated FFR-IQ™ bring anatomy, biology, and physiology together in one comprehensive view of coronary disease. Sessions to note: 🔬 TCT AI Lab 3 | 12:20–1:50 PM Real World Applications of AI: AI-Powered CT for Interventional Procedures Featuring a lecture by Jagat Narula, MD, PhD. 🫀 Training Pavilions | 2:00–3:30 PM & 4:00–5:30 PM Integrating Plaque Biology and BioIntegrated FFR-CT for Lesion-Level Risk Assessment: Hands-on sessions featuring Amir Ahmadi, MD; Hiram G. Bezerra, MD, PhD; and Hector M. Garcia-Garcia, MD, PhD. We look forward to connecting with the interventional cardiology community and advancing the conversation around the future of coronary imaging! #TCT2026 #FFRCT #CCTA #interventionalcardiology #cardiovascularIimaging

Join Dr. Amir Ahmadi alongside renowned interventional cardiologist Dr. Gregg Stone for an upcoming sponsored webinar hosted by SCCT on October 28, 1PM ET: CCTA 3.0: From Plaque to Precision Connecting Lesion-Level Risk with Personalized Patient Therapy Together, they'll explore how emerging approaches to coronary imaging are connecting plaque biology, physiology, and lesion-level risk with more personalized treatment strategies, including the evolving roles of systemic medical therapy and focal intervention. Moderated by Dr. Praveen Ranganath, this discussion will examine the latest evidence and what it could mean for the future of cardiovascular care. 📅 Wednesday, October 28, 2026 🕐 1:00 PM ET 🔗 Register now: scct.org/events/EventDetails… Thank you@Heart_SCCT! #CCTA #SCCT #cardiovascularimaging #precisionmedicine #interventionalcardiology

👋 We're thrilled to welcome Mark Miller to Elucid, as we continue expanding access to our cardiovascular imaging technology! He joins us at an exciting point in our growth as we expand commercialization, strengthen our partnerships across the cardiovascular community, and continue our mission to advance more personalized cardiovascular care. Read the news here: elucid.com/elucid-appoints-m… #cardiovascularimaging #cardiology #medtech #leadership

Come see us at #NASCI2026 today for a hands-on look at Elucid’s CT analysis software offering plaque analysis and BioIntegrated FFR-CT*! #CCTA #cardiovascularimaging #atherosclerosis #cardiology *FFR-CT is under FDA review.

#VPM2026 was simply stellar, as always. We’re still reflecting on the ideas, science, and conversations that came out of this year’s meeting. Bringing together experts from across the field to openly exchange perspectives on vulnerable plaque, atherosclerosis, and the future of cardiovascular care is what makes VPM such a valuable forum. Thank you to everyone who shared their expertise, challenged conventional thinking, and left us with new ideas and inspiration to bring back to our work at Elucid 🫀🧠 Stay tuned for our presentations from the meeting! #vulnerableplaque #cardiovascularimaging #atherosclerosis #CCTA

Elucid is proud to support and exhibit at @NASCISociety Annual Meeting, September 26–29 in Denver. Stop by our booth for a hands-on look at our latest developments and see how we’re advancing CCTA beyond anatomy alone, bringing together anatomy, plaque biology, and physiology for a more complete view of coronary disease. We’re looking forward to connecting with the cardiovascular imaging community, sharing ideas, and demonstrating what becomes possible with Elucid. See you at NASCI! Lesion-Level Risk → Patient-Level Impact #NASCI2026 #CCTA #cardiacCT #cardiovascularimaging #cardiology

❗JUST ANNOUNCED❗ A major milestone for Elucid—and for the future we’re building in cardiovascular care. Read here: elucid.com/elucid-raises-55-… We’re proud to announce the closing of an oversubscribed $55 million Series D financing, bringing Elucid’s total funding raised to approximately $185 million. The round includes new participation from a leading medtech company—our fourth publicly traded strategic investor—alongside new and existing investors. Ultimately, this milestone is about what comes next. As CEO Kelly Huang, PhD, shared: “Analogous to oncology’s shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalized treatment to coronary artery disease management.” We’re grateful to our investors, partners, customers, and the entire Elucid team for helping us reach this moment. There’s much more ahead!! #cardiology #cardiovascularimaging #yesCCT #artificialintelligence #medtech #precisionmedicine

We’re honored to support the Imperial Vulnerable Plaque and Patient Meeting (VPM) for another year! VPM brings together some of the leading minds in atherosclerosis, cardiovascular imaging, and intervention for the kind of focused scientific exchange that makes this meeting so special. This year’s conversations feel especially timely as the field continues to look beyond anatomy alone, and instead toward a deeper understanding of plaque biology, lesion-level risk, and increasingly personalized cardiovascular care. CEO Kelly Huang, and Lead Scientific Advisor @amir_ahmadi__, will be joining the community in Portugal, and we’re looking forward to the ideas, debate, and collaboration ahead. See you in beautiful Vilamoura! 🇵🇹 @MillbrookMed @imperialcollege #vulnerableplaque #cardiology #atherosclerosis #cardiovascularimaging #CCTA #precisionmedicine

What separates meaningful healthcare AI from the hype? For Elucid CEO Kelly Huang, it comes down to what AI enables physicians to understand, and whether that information can lead to a better-informed clinical decision. In a new @AdvaMedUpdate \ Insight Series: AI & Digital Health interview (advamed.org/2026/08/27/the-i…), Kelly discusses why the next generation of cardiovascular AI needs to go beyond efficiency alone. He explores the evolution toward CCTA 3.0, where anatomy, plaque biology, and physiology come together at the lesion level; the importance of transparent, explainable and scientifically validated AI; and why directly understanding a patient’s disease could help enable more personalized cardiovascular care. As Kelly puts it: “We can’t out-efficiency a diagnostic blind spot.” Thank you to AdvaMed for the opportunity to share our perspective on where AI can make a meaningful difference in cardiovascular care. #AIinhealthcare #digitalhealth #cardiology #cardiovascularimaging #CCTA #precisionmedicine #medtech

“The lesion is where risk becomes an event.” Individual plaques are where pathways of atherosclerosis progression, rupture, and erosion ultimately converge. By better characterizing risk at the lesion level, and then combining those insights to understand the patient as a whole, we can move toward more personalized risk assessment and, ultimately, more personalized therapy. See the full symposium for the broader discussion on CCTA 3.0, plaque biology, physiology, workflow, and the future of personalized cardiovascular care. Excerpt featuring Dr. Michael Hadley, Northwell. 📺: youtube.com/watch?v=Tz6MCKEI… #yesCCT #cardiology #cardiovascularimaging #coronaryarterydisease #precisionmedicine #medtech

youtube.com/watch?v=0baR_-3k… Elucid CEO Kelly Huang, PhD recently shared our vision for where cardiovascular imaging is headed next: CCTA 3.0. The core idea is simple: anatomy, plaque biology, and physiology should not be viewed in isolation. By integrating all three at the lesion level, physicians can gain a more complete understanding of disease and move toward more personalized treatment decisions. Hear about the scientific foundation behind Elucid’s approach, from histology-based plaque characterization and BioIntegrated FFR-CT* to transparency, workflow, and the clinical research needed to advance lesion-level risk assessment. *FFR-CT is under FDA review. #SCCT2026 #yesCCT #cardiology #cardiovascularimaging #AIinhealthcare #precisionmedicine

In this excerpt from our recent webinar, Dr. Hiram Bezerra walks through a complex multi-vessel case and shows how he used #CCTA-based plaque composition, lesion distribution, and physiology to plan procedural strategy in advance. 📺 Full webinar: youtu.be/YyS0DX6e3eA?si=q5Qs… #cardiology #interventionalcardiology #yesCCT #coronaryarterydisease #plaqueanalysis #cathlab #precisionmedicine

Can two coronary lesions with the same degree of stenosis behave differently? In this clip, @amir_ahmadi__ explains why coronary arteries can't simply be thought of as rigid pipes. Plaque composition, vessel remodeling, and the biological behavior of the vessel during maximal hyperemia all influence physiology, meaning lesions with similar anatomical narrowing may produce very different functional outcomes. It's one reason why the future of #yesCCT lies in integrating plaque biology and lesion-level physiology, providing a deeper understanding of coronary artery disease and supporting more personalized clinical decision-making. Full webinar featuring Dr. Amir Ahmadi and Dr. Hiram Bezerra: youtube.com/watch?v=YyS0DX6e… #cardiology #CCTA #cardiovascularimaging #precisionmedicine #medtech

For years, cardiovascular risk assessment has often focused on individual measures such as stenosis, plaque composition, and physiology as if they were competing ways to understand disease. In our recent webinar hosted by @Heart_SCCT, @amir_ahmadi__ shares why that paradigm is changing. With today's advances in CCTA and AI, these previous competing metrics have become complementary components of a more complete understanding of coronary artery disease. The future lies in integrating plaque biology, lesion-level physiology, and anatomy into a single comprehensive assessment, enabling physicians to move from lesion-level risk to patient-level impact and support more personalized clinical decision-making. Watch the full webinar, including case discussions with Dr. Hiram Bezerra and a look at how comprehensive CCTA analysis may help inform interventional planning: 📺 youtube.com/watch?v=YyS0DX6e… #cardiology #yesCCT #precisionmedicine #coronaryarterydisease #cardiovascularimaging #medtech

Stop by booth 210 today at #ASPC2026 to experience a live demo of our latest product features! Come see how a comprehensive plaque analysis joining biology and physiology can enhance your preventive cardiology program. @ASPCardio

Last chance to register ➡️ scct.org/events/EventDetails… Don't miss out on the opportunity to hear from Dr. Amir Ahmadi (@amir_ahmadi__) and Dr. Hiram Bezerra as they explore what's driving the evolution of CCTA 3.0: from advanced plaque analysis and lesion-level physiology to the latest interventional therapies that are changing how we diagnose and treat coronary artery disease. We'll also be sharing case demonstrations, discussing upcoming clinical research, and answering your questions live. Thank you @Heart_SCCT for hosting! #cardiology #yesCCT #cardiovascularimaging #precisionmedicine #medtech #preventivecardiology #interventionalcardiology